memantine chanelle medical 10 mg/ ml oral solution
10 mg/ ml oral solution
memantine cipla 20 mg film - coated tablets
20 mg film - coated tablets
memantine cipla 10 mg film - coated tablets
10 mg film - coated tablets
memantine teva 10 mg orodispersible tablets
10 mg orodispersible tablets
memantine teva 20 mg orodispersible tablets
20 mg orodispersible tablets
antisedan vet 5 mg/ml solution for injection 5 mg/ml
orion corporation - Тук се намира хидрохлорид - инжекционен разтвор - 5 mg/ml - котки, кучета
anti - chf vaccine suspension for injection
БУЛ БИО - НЦЗПБ ЕООД - Кримската хеморагична треска ваксини; инактивированные - suspension for injection
snake venom antiserum bul bio solution for injection
БУЛ БИО - НЦЗПБ ЕООД - Вайпер веном антисыворотка - solution for injection
xeljanz
pfizer europe ma eeig - Тофацитиниб - Артрит, ревматоиден - Имуносупресори - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 и 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.